Compare Immunovant Inc. Common Stock (IMVT) vs IAC/Interactivecorp (PPLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs IAC/Interactivecorp — how do they compare? Immunovant Inc. Common Stock trades at $30.25 (market cap $6.25B), while IAC/Interactivecorp trades at $40.94 (market cap $3.05B). The key difference: Immunovant Inc. Common Stock is far larger — about 2× IAC/Interactivecorp's market cap, and IAC/Interactivecorp is trading nearer its 52-week high, Immunovant Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and IAC/Interactivecorp for 79 Days on average.
| IMVT | PPLI | |
|---|---|---|
Market Cap | $6.25B | $3.05B |
Volume | 1,755,411 | 931,019 |
Sector | Health | Media |
52-Week High | $44.96 | $47.62 |
52-Week Low | $17.03 | $31.52 |
Typical Hold Time | 0 Days | 79 Days |
Enterprise Value | $5.35B | $3.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
PPLI trades at $40.59, down 1.7% in the past 24 hours, with a bullish technical signal from moving averages. The stock shows mixed fundamentals: revenue declined to $2.39B in 2025 with a net loss of $104.03M, but valuation ratios appear attractive with a P/E of 6.87 and P/B of 0.59. Recent news highlights potential M&A activity, as MGM Resorts is reportedly considering a bid for PPLI, following PPLI's withdrawal of its own offer to buy MGM.
The outlook is cautiously optimistic, supported by strong analyst consensus (71.4% buy ratings) and potential upside from strategic deals. Key risks include inconsistent profitability, high debt levels, and execution challenges in a competitive media landscape. Earnings volatility remains a concern, but the low valuation and M&A speculation provide catalysts for investor interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →
